Summary
Biomedical engineering and healthcare technology sits between device design, regulatory approval, clinical use and maintenance. The sources in this pack describe a large and growing global device sector, with diagnostics and imaging as leading revenue areas and original equipment manufacturers holding the largest share of engineering value 67. US FDA data show high submission volumes, a fast-growing count of AI-enabled devices and a premarket approval pathway that remains slow 145. The main risks are regulatory timelines, staffing limits on oversight, and the lack of verified data on workforce, waiting times, reimbursement and access by income group. Market-size estimates also conflict across research firms. Outlook: AI-enabled device authorizations and digital features are likely to keep rising, but the pace depends on regulatory capacity and on evidence that the sources do not yet quantify. Stakeholders should plan around these gaps rather than around single headline forecasts.
Key findings
-
1
The FDA received more than 21,700 submissions in the latest full year and authorized 5,640 marketing submissions.
Submission volume rose by about 1,000 from the prior year, and authorizations were slightly above the prior year's count. Novel device authorizations numbered 124. These are US figures and measure regulatory throughput, not device quality.
Confidence: High -
2
AI-enabled device authorizations are rising quickly in the US.
The FDA authorized 335 AI-enabled devices in the latest year, up from 235 in the prior year, bringing the cumulative total to 1,433. About 96.1% of these were cleared through 510(k). Counts come from a secondary database summary.
Confidence: Medium -
3
Premarket approval timelines lengthened sharply in the latest year-to-date data.
Average time to PMA approval was about 598.5 days, compared with about 401.7 days in the prior comparable period. An analyst view that excludes three outliers puts the figure near 339 days. The analysis is from an industry news report citing a broker analyst.
Confidence: Medium -
4
Market-size estimates are not consistent across research firms.
One firm values the global medical device engineering market at USD 9.96 billion and projects USD 26.16 billion. Another reports a medical device technologies market of USD 0.68 trillion, projected to reach USD 1.02 trillion. The definitions differ, and neither estimate has been reconciled.
Confidence: Qualitative -
5
Regulatory staffing and access are documented concerns, but workforce and access data are missing.
A GAO report, cited secondarily, found staffing constraints limited FDA oversight of device recalls. WHO describes medical device access as a global priority and has launched open tools, but the pack contains no verified waiting-time, workforce or income-group access figures.
Confidence: Qualitative
1Industry definition and scope
This report covers biomedical engineering and healthcare technology as the design, development, evaluation, regulation, maintenance and clinical support of medical devices and related health technologies. The WHO estimates that more than 10,000 different medical devices are used globally for protection, prevention, diagnosis, treatment or rehabilitation 8. The scope therefore spans diagnostic instruments, imaging systems, implants, monitoring tools and digital health software.
The geographic scope is global. Where detail is available, the report uses US Food and Drug Administration data, because it is the most complete national source in the pack. Figures are labeled as observed, estimated or forecast according to the source.
Terminology varies. Market research firms use different labels, such as medical device engineering, medical device technologies and medical devices, and their boundaries do not match. This report treats these as related but non-identical measures. The WHO Global Atlas covers country profiles on device policy, regulation, health technology assessment and biomedical engineering resources, which places the field within health system planning 10.
Interpretation: the specialty is best understood as a link between manufacturers, regulators and health services, rather than as a single product market.
- Medical devices used globally (different types) 10,000devices Observed Global, Current (undated in source) [8]
Scope definitions follow the terms used by the cited sources. No single definition is verified across all of them.
Assumptions behind these figures
- Device counts are taken as stated by WHO and are not reconciled with other device databases.
2Market size, structure and value chain
One market research estimate values the global medical device engineering market at USD 9.96 billion in the latest year, with growth to USD 26.16 billion projected for a later period 6. This is an estimate and a forecast from a vendor-style research firm, so it should be treated as directional. A separate estimate covers medical device technologies, which it places at USD 0.68 trillion in the base year and USD 1.02 trillion in the forecast 7. The gap between these figures reflects different scope, not a verified difference in growth.
Regional structure is concentrated. North America held nearly 39% of revenue share in the latest year 6. The same source reports that medical device original equipment manufacturers held about 65% of the market 6. This suggests that manufacturers capture most of the engineering value, while engineering service providers, contract developers and maintenance organizations hold the remainder. The pack does not quantify that remainder.
Diagnostic devices led the technology segment with 39.12% of revenue in the latest year, supported by installed bases of MRI, CT and ultrasound equipment 7. Installed-base revenue suggests recurring service and maintenance income, but the pack gives no figures for service revenue.
Value chain stakeholders include device designers, OEMs, engineering service firms, regulators, health technology assessment bodies, providers and maintenance teams. Revenue models range from one-time equipment sales to service contracts and software licensing. Only the first is quantified in the pack.
- Global medical device engineering market value 9.96USD billion Estimate Global, Latest available year [6]
- North America share of medical device engineering revenue 39percent Observed Global (North America), Latest available year [6]
- Medical device OEM share of market 65percent Observed Global, Latest available year [6]
Market values are vendor estimates. The report does not reconcile them and does not treat the forecast as a certain outcome.
Assumptions behind these figures
- Share figures from the market research source are assumed to be on a comparable revenue basis.
3Customers, demand and adoption
The main end users are health systems, hospitals, clinics, laboratories and patients. The pack does not report purchasing decisions, procurement criteria or adoption rates by provider type, so public, private and community providers cannot be compared on device adoption, quality or cost. This is a major gap.
Demand signals in the pack come mainly from regulators and product developers. The FDA reports that 54% of premarket applications included patient-reported outcomes 1. This shows that evidence expectations are widening beyond device performance tests, although the figure does not show whether those outcomes changed purchasing decisions.
Digital and AI-enabled devices are one clear area of demand growth. Authorizations rose to 335 in the latest year 4. Purchasing criteria for these products are not documented in the pack. Interpretation: buyers are likely to ask for regulatory clearance, interoperability and evidence of performance in real settings, but the sources do not verify this.
Barriers to adoption include regulatory time and cost. Average PMA approval time is reported at several hundred days 5. Reimbursement and funding figures for biomedical engineering or digital health devices were not retrieved, so the report cannot assess affordability for end users.
Equity is a stated concern. WHO describes device access as a route to universal health coverage, but no verified figures by income group were retrieved 10.
Demand discussion relies on regulatory activity data. No demand or utilization measures for care services were verified.
Assumptions behind these figures
- Patient-reported outcome inclusion is treated as an evidence expectation, not as a proven driver of purchasing.
4Competitive landscape and key players
The pack does not name competing device manufacturers with revenue, market share or product comparisons, so this section compares provider types rather than companies. Comparable company examples were limited in the sources.
Original equipment manufacturers hold about 65% of the engineering market 6. Their business model depends on regulatory clearance and on products that can be manufactured at scale. Engineering service firms serve manufacturers with design and testing work, and their share is not quantified. Regulators and standards bodies do not compete, but they shape entry, cost and timing.
Diagnostic devices hold the largest technology share at 39.12% 7. Imaging installed bases suggest concentrated competition among large equipment suppliers, but no supplier-level data are in the pack, so concentration cannot be measured beyond the OEM share.
Competitive pressure is shaped by pathway choice. Nearly 99% of devices enter the US market through 510(k) rather than premarket approval 2. This means most entrants face a faster route, which lowers barriers for new products but increases competition on evidence and differentiation.
Fair comparison requires company-level financial and quality data, which the pack does not provide. Public and private providers are not compared here for the same reason.
Company examples are restricted to regulators and international bodies in the pack. No commercial company performance data were verified.
Assumptions behind these figures
- The OEM share is treated as an indicator of concentration, not as a measure of competitive strength.
5Technology, operations and workforce
Established practice is dominated by 510(k) clearance. Its share of AI-enabled device authorizations is 96.1% cumulatively 4, which shows that most AI tools reach the market through the same route as conventional devices. This is a mature pathway applied to a newer technology class.
Emerging technology is concentrated in AI-enabled software and digital monitoring. The cumulative count of 1,433 authorized AI-enabled devices is a sign of rapid expansion 4. Experimental or early-stage use cases are not separately quantified in the pack, so the boundary between established and emerging practice is an interpretation.
Operationally, device maintenance and recall oversight depend on regulator capacity. A GAO report, cited secondarily, found that staffing constraints limited FDA oversight of recalls 2. This suggests a link between regulator staffing and safety monitoring, though the pack does not quantify the effect.
Workforce data are missing. No verified figures on clinical engineering staff size, staffing ratios or vacancy rates were retrieved. The report therefore cannot assess shortages or skill supply directly.
- AI-enabled devices authorized by the FDA in the latest year 335devices Observed United States, Latest calendar year [4]
Productivity and workforce claims are not quantified. Operational effects are described qualitatively.
Assumptions behind these figures
- Cumulative AI device counts are drawn from a secondary database and may differ from the FDA primary list.
6Regulation, standards, risk and sustainability
Jurisdiction: the most detailed regulatory data in the pack are from the United States. US pathways include 510(k) premarket notification and premarket approval (PMA). PMA is described as the most complex pathway, with typical processing above one year 3. These pathways are binding legal routes under US law as described by the sources. Users should confirm current requirements with the FDA or qualified counsel.
WHO instruments, including the MeDevIS clearing house and priority device lists, are described as tools to support access and appropriate use 89. They are not presented in the pack as binding regulatory requirements. Proposed rules and draft guidance were not retrieved.
Safety depends on post-market surveillance. The staffing constraints reported for recall oversight are a material risk to safety monitoring 2. The pack does not provide recall counts or safety outcome data.
Privacy, data protection and environmental sustainability were not covered by the verified sources. Ethics of AI use in clinical settings is noted only as an area needing evidence. These are gaps, not findings.
This report is general industry analysis. It is not professional medical, legal, investment or engineering advice.
Binding and voluntary instruments are separated as the sources describe them. Primary legal texts were not retrieved.
Assumptions behind these figures
- Regulatory descriptions reflect the cited secondary summaries and should be checked against primary FDA and WHO documents.
7Challenges, opportunities and case examples
The main constraint is regulatory time. Average PMA approval time rose to about 598.5 days in the latest year-to-date period, compared with about 401.7 days in the prior comparable period. Excluding three outliers, the analyst's figure is about 339 days 5. The outlier effect shows that averages are sensitive to a few long reviews, so the median is a better planning figure, though the pack does not provide one.
A second constraint is capacity to monitor devices after authorization. The GAO finding on staffing 2 points to a gap between market growth and oversight capacity.
Opportunities include growth in AI-enabled devices 4 and the WHO push for shared information on devices 8. Case example one: the WHO MeDevIS platform is described as the first global open access clearing house for information on medical devices 8. It is an institutional example, not a company example. Case example two: the WHO priority device list for cardiovascular disease and diabetes listed 1,500 devices at its launch 9, showing how a public list can shape access priorities.
Case example three: the FDA's annual report shows high submission volumes, which indicates strong regulatory throughput 1. Comparable company case studies were limited in the sources.
| Measure | Days | Basis |
|---|---|---|
| Average time to PMA approval, latest year-to-date | 598.5 | Observed, analyst report |
| Average time to PMA approval, prior comparable period | 401.7 | Observed, analyst report |
| Average excluding three outliers, latest year-to-date | 339 | Observed, analyst view |
Case examples are institutional. Commercial company examples were limited in the pack.
Assumptions behind these figures
- The analyst's outlier exclusion is taken as reported and has not been independently tested.
8Outlook and strategic implications
Near term, the most likely pattern is continued growth in AI-enabled authorizations and in device submissions, consistent with the recorded trends 14. This is an interpretation of past counts, not a verified forecast.
Medium term, the pace of approvals depends on whether PMA timelines ease. The sharp rise in average approval time 5 is a reason to watch regulatory capacity closely. Forecast market values differ by source 67, so planners should use ranges, not single numbers.
Uncertainties include regulatory staffing, reimbursement, workforce supply and access by income group. None of these is quantified in the verified pack.
Implications: manufacturers should plan for longer review times and for evidence expectations such as patient-reported outcomes 1. Health systems should build maintenance and monitoring capacity. Regulators and WHO should publish workforce and access data. Investors and researchers should treat vendor forecasts as directional only.
Outlook combines recorded counts with stated gaps. It does not use unsupported projections.
Assumptions behind these figures
- Scenario statements are interpretations of recorded trends and are not forecasts from the sources.
9Conclusion
The verified evidence points to a large, growing and concentrated global device sector, with rapid growth in AI-enabled authorizations and slow premarket approval timelines in the US. The most defensible takeaway is that regulatory capacity and evidence requirements now shape the pace of the field, while workforce, access and cost remain unmeasured in the sources.
How this was built
The report uses a global scope with US FDA data as the national example. Figures are labeled by type, and forecasts and vendor estimates are separated from observed counts. Market-size figures are not reconciled across sources.
Limits to keep in mind
- No verified global figures on biomedical engineering or clinical engineering workforce size, staffing ratios or vacancy rates.
- No verified waiting-time or hospital capacity indicators for equipment maintenance or imaging access.
- No verified public versus private provider comparison of device adoption, quality or cost.
- WHO regional factsheet figures on regulatory authority maturity were not verified and are excluded.
- Market-size estimates differ widely across research firms and are not reconciled.
- No verified reimbursement or funding figures for biomedical engineering or digital health devices.
Sources
-
1
U.S. FDA Issues Annual Report on Medical Device Regulatory Activities
emergobyul.com -
2
FDA 510(k) Explained: Medical Device Premarket Notification
intuitionlabs.ai -
3
FDA Premarket Approval (PMA)
blog.johner-institute.com -
4
FDA authorized 335 AI-enabled medical devices in the latest year, bringing the total since the program began to 1,433
aiadoption.org -
5
FDA Approval Timelines Found to Be More Challenging in the Latest Period
mddionline.com -
6
Medical Device Engineering Market to Expand to USD 26.16 Bn in the Forecast Period
towardshealthcare.com -
7
Medical Device Technologies Market Share & Statistics (latest edition)
mordorintelligence.com -
8
WHO MeDevIS platform announced to boost access to medical technologies and devices
who.int -
9
WHO launches List of Priority Medical Devices for management of cardiovascular diseases and diabetes
who.int -
10
Global atlas of medical devices (latest edition)
who.int